US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Artiva Biotherapeutics, Inc.

2.33

-0.1200-4.90%

Volume:23.44K

Turnover:54.94K

Market Cap:56.77M

PE:-0.40

High:2.42

Open:2.42

Low:2.29

Close:2.45

Loading ...

Overview Company News Filings

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Names New Chief Medical Officer

Artiva CMO Thorsten Graef switches to advisor role, Subhashis Banerjee succeeds

Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Artiva Biotherapeutics Price Target Maintained With a $23.00/Share by Needham

Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Analysts Are Bullish on These Healthcare Stocks: Artiva Biotherapeutics, Inc. (ARTV), Corvus Pharmaceuticals (CRVS)

Artiva Biotherapeutics Is Maintained at Overweight by Cantor Fitzgerald

Artiva Biotherapeutics Price Target Maintained With a $23.00/Share by Needham

Artiva Biotherapeutics 2024 EPS $(5.81), Total Revenue $251K Down From $33.49M YoY

Artiva Biotherapeutics : Initial Data for Allonk From Autoimmune Program Expected H1 2025

THOMSON REUTERS

Artiva Biotherapeutics: Expected to Fund Operations at Least Through End of 2026

THOMSON REUTERS

Press Release: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Expands Board of Directors With Appointment of Dan Baker, M.d.

THOMSON REUTERS

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

HC Wainwright Initiates Artiva Biotherapeutics at Buy With $20 Price Target

MT Newswires Live

BUZZ-H.C. Wainwright starts coverage of Artiva Biotherapeutics with 'buy' rating

Artiva Biotherapeutics Initiated at Buy by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARTV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARTV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARTV\",,,,,undefined,":{"symbol":"ARTV","market":"US","secType":"STK","nameCN":"Artiva Biotherapeutics, Inc.","latestPrice":2.33,"timestamp":1746028508647,"preClose":2.45,"halted":0,"volume":23441,"delay":0,"floatShares":4396863,"shares":24363119,"eps":-5.806365,"marketStatus":"Trading","change":-0.12,"latestTime":"04-30 11:56:21 EDT","open":2.42,"high":2.42,"low":2.29,"amount":54939.445253,"amplitude":0.053061,"askPrice":2.35,"askSize":100,"bidPrice":2.31,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-5.806365,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"listingDate":1721361600000,"exchange":"NASDAQ","adjPreClose":2.45,"preHourTrading":{"tag":"盘前","latestPrice":2.4146,"preClose":2.45,"latestTime":"09:13 EDT","volume":245,"amount":586.7295035000001,"timestamp":1746018782255},"postHourTrading":{"tag":"盘后","latestPrice":2.45,"preClose":2.45,"latestTime":"17:51 EDT","volume":601,"amount":1472.7293,"timestamp":1745963488026},"volumeRatio":0.299533},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARTV\",,,,,undefined,":{"symbol":"ARTV","floatShares":4396863,"roa":"-26.72%","roe":"-54.24%","lyrEps":-5.806365,"volumeRatio":0.299533,"shares":24363119,"dividePrice":0,"high":2.42,"amplitude":0.053061,"preClose":2.45,"low":2.29,"week52Low":1.78,"pbRate":"0.30","psRate":"226.16","week52High":17.31,"institutionHeld":0,"latestPrice":2.33,"committee":-0.666667,"eps":-5.806365,"divideRate":0,"volume":23441,"delay":0,"ttmEps":-5.806365,"open":2.42,"prevYearClose":10.08,"prevWeekClose":2.47,"prevMonthClose":3,"prevQuarterClose":3,"fiveDayClose":2.45,"twentyDayClose":3,"sixtyDayClose":4.89},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARTV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531298353","title":"Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531298353","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531298353?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:35","pubTimestamp":1745872500,"startTime":"0","endTime":"0","summary":"Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK + rituximab for the treatment of B-cell driven diseases in a community setting. Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process. In addition, the Company will have a poster presentation featuring the scalability and consistency of the AlloNK manufacturing process.Abstract 858 – AlloNK Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Abstract 1765 – AlloNK: A Scalable and Consistent NK Cell Therapy in Development for Treatment of Oncology and Autoimmune Diseases. Abstracts are currently available on the ASGCT website. Following the presentations, copies will be available on the \"Scientific Posters & Publications\" section of the “Events & Presentation” page on the Company's website.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/artiva-biotherapeutics-present-longer-term-203500617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2526823264","title":"Artiva Biotherapeutics Names New Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526823264","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526823264?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:57","pubTimestamp":1744145820,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics named Subhashis Banerjee as its chief medical officer, succeeding Thorsten Graef, who will continue to serve the company as a strategic adviser.Banerjee is a trained rheumatologist and immunologist with more than two decades of clinical development experience in autoimmune diseases, the San Diego-based company said Tuesday.His appointment will help the company progress the clinical development of its treatment of B-cell driven autoimmune diseases, Chief Executive Fred Aslan said.Prior to joining Artiva, Banerjee helmed Bristol Myers Squibb's rheumatology and dermatology global development arm. Previously, he held an executive position at Vyne Therapeutics.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARTV"],"gpt_icon":0},{"id":"2526823067","title":"Artiva CMO Thorsten Graef switches to advisor role, Subhashis Banerjee succeeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2526823067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526823067?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:45","pubTimestamp":1744145135,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics (ARTV) announced the appointment of Subhashis Banerjee as chief medical officer. Banerjee was most recently disease area hea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/artiva-cmo-thorsten-graef-switches-to-advisor-role-subhashis-banerjee-succeeds?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/artiva-cmo-thorsten-graef-switches-to-advisor-role-subhashis-banerjee-succeeds?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2526384049","title":"Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526384049","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526384049?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy. Dr. Banerjee added, \"Artiva is leading the development of NK cell treatments for autoimmune disease, with the potential to offer a much-needed, long-term therapeutic option with an accessibility and safety profile that enables broad use in a community setting. The robust B-cell depletion seen with AlloNK through enhanced antibody-directed killing of cells in non-Hodgkin lymphoma bodes well for our opportunity to deeply deplete B-cells in patients with autoimmune diseases and to bring about meaningful clinical improvements and medication reductions. Artiva has built a very seasoned development team, and I am excited to lead the effort to further define the indications where AlloNK can be most impactful, and to help drive the program towards late-stage development.\"","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IIM","RA","BK4022","R","SLE","ARTV","BK4232","BK4139","BMS","BK4077"],"gpt_icon":0},{"id":"2525928318","title":"Artiva Biotherapeutics Price Target Maintained With a $23.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2525928318","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525928318?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:53","pubTimestamp":1744116780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 08:53 ET (12:53 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2525601798","title":"Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2525601798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525601798?lang=en_us&edition=fundamental","pubTime":"2025-04-08 18:57","pubTimestamp":1744109876,"startTime":"0","endTime":"0","summary":"Analyst Gil Blum from Needham maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) and keeping the price target at $23....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-outlook-for-artiva-biotherapeutics-amid-strategic-manufacturing-and-regulatory-support?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-outlook-for-artiva-biotherapeutics-amid-strategic-manufacturing-and-regulatory-support?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2524974258","title":"Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524974258","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524974258?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:05","pubTimestamp":1743451500,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March  31, 2025  (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052765/0/en/Artiva-Biotherapeutics-to-Participate-in-the-24th-Annual-Needham-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","ARTV","BK4139","HCSG"],"gpt_icon":0},{"id":"2522827216","title":"Artiva Biotherapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522827216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522827216?lang=en_us&edition=fundamental","pubTime":"2025-03-26 18:51","pubTimestamp":1742986260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 06:51 ET (10:51 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2522132821","title":"Analysts Are Bullish on These Healthcare Stocks: Artiva Biotherapeutics, Inc. (ARTV), Corvus Pharmaceuticals (CRVS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522132821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522132821?lang=en_us&edition=fundamental","pubTime":"2025-03-26 18:20","pubTimestamp":1742984440,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Artiva Biotherapeutics, Inc. (ARTV – Research Report...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-artiva-biotherapeutics-inc-artv-corvus-pharmaceuticals-crvs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-artiva-biotherapeutics-inc-artv-corvus-pharmaceuticals-crvs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4137","ARTV","CRVS","HCSG","BK4139"],"gpt_icon":0},{"id":"2522070135","title":"Artiva Biotherapeutics Is Maintained at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2522070135","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522070135?lang=en_us&edition=fundamental","pubTime":"2025-03-25 22:06","pubTimestamp":1742911560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 10:06 ET (14:06 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2522040879","title":"Artiva Biotherapeutics Price Target Maintained With a $23.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2522040879","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522040879?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:49","pubTimestamp":1742899740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 06:49 ET (10:49 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2522083476","title":"Artiva Biotherapeutics 2024 EPS $(5.81), Total Revenue $251K Down From $33.49M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2522083476","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522083476?lang=en_us&edition=fundamental","pubTime":"2025-03-25 05:15","pubTimestamp":1742850945,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics 2024 EPS $(5.81), Total Revenue $251K Down From $33.49M YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44466321/artiva-biotherapeutics-2024-eps-5-81-total-revenue-251k-down-from-33-49m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSS","ARTV"],"gpt_icon":0},{"id":"2522707579","title":"Artiva Biotherapeutics : Initial Data for Allonk From Autoimmune Program Expected H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707579?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:06","pubTimestamp":1742846763,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q70WW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2522520707","title":"Artiva Biotherapeutics: Expected to Fund Operations at Least Through End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520707?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:06","pubTimestamp":1742846763,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q70WW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2522707632","title":"Press Release: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707632","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707632?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:05","pubTimestamp":1742846700,"startTime":"0","endTime":"0","summary":"Initial data for AlloNK from autoimmune program expected H1 2025. Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025. Strengthened key leadership with cell therapy and autoimmune expertise across organization. Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026. SAN DIEGO, March 24, 2025  -- Artiva Biotherapeutics, Inc.  , a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress.Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","RA","BK4077","BK4232","BK4139","BK4022","ARTV","SLE"],"gpt_icon":0},{"id":"2507663435","title":"Artiva Biotherapeutics Expands Board of Directors With Appointment of Dan Baker, M.d.","url":"https://stock-news.laohu8.com/highlight/detail?id=2507663435","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507663435?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:05","pubTimestamp":1738184701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nTUA6S8GJC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"gpt_icon":0},{"id":"2507066303","title":"Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.","url":"https://stock-news.laohu8.com/highlight/detail?id=2507066303","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507066303?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:05","pubTimestamp":1738184700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan.  29, 2025  (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell ther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/29/3017563/0/en/Artiva-Biotherapeutics-Expands-Board-of-Directors-with-Appointment-of-Dan-Baker-M-D.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","IE00B3PB1722.GBP","LU1674673428.USD","LU1718418525.SGD","LU1066051498.USD","LU1674673691.USD","IE00B4R5TH58.HKD","LU0234572021.USD","LU1732799900.SGD","IE0002270589.USD","IE0034235303.USD","LU1914381329.SGD","LU0203347892.USD","LU0912757837.SGD","LU1506573853.SGD","LU0795875086.SGD","LU1280957306.USD","LU2468319806.SGD","BK4592","BK4550","JNJ","ARTV","LU2089984988.USD","IE00B7SZLL34.SGD","IE00BVYPNW00.USD","IE00BDGV0183.EUR","LU0345770993.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU0466842654.USD","LU1059921491.USD","LU0889566641.SGD","LU1066053197.SGD","LU0795875169.SGD","LU1074936037.SGD","LU2112291526.USD","LU0792757196.USD","IE00B1BXHZ80.USD","LU1221951046.USD","LU2602419157.SGD","IE00BSNM7G36.USD","CEO","IE00B19Z3581.USD","BK4588","BK4534","LU1032955483.USD","SG9999002232.USD","LU1430594728.SGD","LU0114720955.EUR","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2495810546","title":"HC Wainwright Initiates Artiva Biotherapeutics at Buy With $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2495810546","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495810546?lang=en_us&edition=fundamental","pubTime":"2024-12-30 20:22","pubTimestamp":1735561323,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics (ARTV) has an average rating of buy and mean price target of $21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARTV"],"gpt_icon":0},{"id":"2495545527","title":"BUZZ-H.C. Wainwright starts coverage of Artiva Biotherapeutics with 'buy' rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2495545527","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495545527?lang=en_us&edition=fundamental","pubTime":"2024-12-30 20:09","pubTimestamp":1735560565,"startTime":"0","endTime":"0","summary":"BUZZ-H.C. Wainwright starts coverage of Artiva Biotherapeutics with 'buy' rating** Brokerage H.C. Wainwright starts coverage of drug developer Artiva Biotherapeutics ARTV.O with \"buy\" rating and PT of $20** PT represents an ~88% upside to stock's last close** Co is testing its experimental drug, AlloNK, for an autoimmune disease called systemic lupus erythematosus  in combination with antibodies Rituxan or Gazyva** SLE is a condition where the immune system attacks the body's own tissues ** Brokerage notes \"current treatment options do not effectively control disease progression\"** Says AlloNK costs less than $6,000 per patient for ARTV to produce, compared to ~$100,000 for auto-CAR T therapies ** Co has capacity to produce enough AlloNK for over 1,000 autoimmune patients annually, H.C. Wainwright says** Brokerage expects AlloNK to launch by 2029 and forecasts sales to grow to $531 mln by 2031** As of last close, stock has fallen ~34% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nL4N3NV0F7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"gpt_icon":0},{"id":"2495543120","title":"Artiva Biotherapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2495543120","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495543120?lang=en_us&edition=fundamental","pubTime":"2024-12-30 19:55","pubTimestamp":1735559700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 30, 2024 06:55 ET (11:55 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARTV\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARTV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARTV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ARTV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ARTV","date":"2025-04-29","current":-0.913063,"percent":0.928962,"low":-11.820615,"twenty":-9.377339,"median":-4.327611,"eighty":-1.598253,"high":-0.685729,"avg":-5.274059,"sd":3.592793,"marketCap":59689641},"quantilePoints":[{"date":"2024-08-02","current":-10.391793,"twenty":-10.391793,"median":-10.391793,"eighty":-10.391793,"marketCap":269833291},{"date":"2024-08-09","current":-9.862789,"twenty":-10.391793,"median":-10.042112,"eighty":-9.943484,"marketCap":256097171},{"date":"2024-08-16","current":-10.185571,"twenty":-10.248334,"median":-10.131774,"eighty":-9.95245,"marketCap":264478532},{"date":"2024-08-23","current":-8.939273,"twenty":-10.248334,"median":-10.051078,"eighty":-9.342751,"marketCap":232117163},{"date":"2024-08-30","current":-8.088598,"twenty":-10.185571,"median":-9.943484,"eighty":-9.046867,"marketCap":263081639},{"date":"2024-09-06","current":-8.893463,"twenty":-10.142533,"median":-9.800025,"eighty":-8.930111,"marketCap":289259885},{"date":"2024-09-13","current":-8.019798,"twenty":-10.131774,"median":-9.459311,"eighty":-8.763533,"marketCap":260843926},{"date":"2024-09-20","current":-8.759053,"twenty":-10.07439,"median":-9.028935,"eighty":-8.450238,"marketCap":284888199},{"date":"2024-09-27","current":-9.946342,"twenty":-10.07439,"median":-9.323455,"eighty":-8.581333,"marketCap":323504758},{"date":"2024-10-04","current":-11.499524,"twenty":-10.277026,"median":-9.57298,"eighty":-8.727691,"marketCap":374022017},{"date":"2024-10-11","current":-10.566121,"twenty":-10.505561,"median":-9.728296,"eighty":-8.794895,"marketCap":343663087},{"date":"2024-10-18","current":-9.543111,"twenty":-10.587029,"median":-9.800025,"eighty":-8.869568,"marketCap":310389700},{"date":"2024-10-25","current":-7.586699,"twenty":-10.505561,"median":-9.574426,"eighty":-8.581333,"marketCap":246757383},{"date":"2024-10-31","current":-7.579232,"twenty":-10.485041,"median":-9.464706,"eighty":-8.226879,"marketCap":246514511},{"date":"2024-11-08","current":-10.424244,"twenty":-10.485041,"median":-9.3863,"eighty":-8.226879,"marketCap":339048530},{"date":"2024-11-15","current":-4.166082,"twenty":-10.46953,"median":-9.378833,"eighty":-8.149728,"marketCap":255280837},{"date":"2024-11-22","current":-4.310765,"twenty":-10.439178,"median":-9.30416,"eighty":-7.969021,"marketCap":264146442},{"date":"2024-11-29","current":-5.065892,"twenty":-10.411264,"median":-9.046867,"eighty":-7.81669,"marketCap":310417611},{"date":"2024-12-06","current":-4.598149,"twenty":-10.334409,"median":-8.970887,"eighty":-7.365669,"marketCap":281756204},{"date":"2024-12-13","current":-4.233469,"twenty":-10.223229,"median":-8.939273,"eighty":-5.058757,"marketCap":259410023},{"date":"2024-12-20","current":-3.963922,"twenty":-10.173512,"median":-8.885996,"eighty":-4.852633,"marketCap":242893280},{"date":"2024-12-27","current":-4.17401,"twenty":-10.150694,"median":-8.781454,"eighty":-4.667914,"marketCap":255766623},{"date":"2025-01-03","current":-3.95203,"twenty":-10.131774,"median":-8.549971,"eighty":-4.598149,"marketCap":242164600},{"date":"2025-01-10","current":-4.066984,"twenty":-10.131774,"median":-8.396892,"eighty":-4.398368,"marketCap":249208505},{"date":"2025-01-17","current":-2.687539,"twenty":-10.07439,"median":-8.17661,"eighty":-4.337719,"marketCap":164681643},{"date":"2025-01-24","current":-2.477451,"twenty":-10.049285,"median":-8.109405,"eighty":-4.224748,"marketCap":151808300},{"date":"2025-01-31","current":-2.140518,"twenty":-10.011532,"median":-8.012331,"eighty":-4.193829,"marketCap":131162371},{"date":"2025-02-07","current":-1.823404,"twenty":-9.967928,"median":-7.881014,"eighty":-4.108209,"marketCap":111730908},{"date":"2025-02-14","current":-1.589533,"twenty":-9.948785,"median":-7.698708,"eighty":-3.978192,"marketCap":97400205},{"date":"2025-02-21","current":-1.502326,"twenty":-9.945199,"median":-7.508293,"eighty":-3.804572,"marketCap":92056553},{"date":"2025-02-28","current":-1.478543,"twenty":-9.911206,"median":-5.18038,"eighty":-2.77871,"marketCap":90599193},{"date":"2025-03-07","current":-2.0216,"twenty":-9.837683,"median":-5.059946,"eighty":-2.521847,"marketCap":123875572},{"date":"2025-03-14","current":-2.219796,"twenty":-9.795827,"median":-4.998506,"eighty":-2.343471,"marketCap":136020236},{"date":"2025-03-21","current":-1.601424,"twenty":-9.736345,"median":-4.76067,"eighty":-2.165887,"marketCap":98128885},{"date":"2025-03-28","current":-1.319282,"twenty":-9.624289,"median":-4.665536,"eighty":-2.054897,"marketCap":86245441},{"date":"2025-04-04","current":-0.946604,"twenty":-9.574715,"median":-4.606077,"eighty":-1.965312,"marketCap":61882322},{"date":"2025-04-11","current":-0.685729,"twenty":-9.561032,"median":-4.439593,"eighty":-1.797242,"marketCap":44828138},{"date":"2025-04-17","current":-0.857161,"twenty":-9.511749,"median":-4.37617,"eighty":-1.744126,"marketCap":56035173},{"date":"2025-04-25","current":-0.913063,"twenty":-9.383313,"median":-4.344458,"eighty":-1.606181,"marketCap":59689641},{"date":"2025-04-29","current":-0.913063,"twenty":-9.377339,"median":-4.327611,"eighty":-1.598253,"marketCap":59689641}],"updateTime":1746027670396}}}